Joinn Therapeutics' collaborative fund gets regulatory approval

Beijing Joinn Laboratories Co., Ltd. (Joinn Therapeutics) announced that its collaborative fund, Huaxia Zhiyuan Venture Capital Investment Fund (Beijing) Partnership (Limited Partnership), has successfully completed its private investment fund registration with the Asset Management Association of China. The fund received its registration certificate, with the registration code SASP05 and registration date of August 27, 2025.

This registration follows Joinn Therapeutics' prior announcement on December 21, 2024, regarding its intention to invest up to RMB 2,000 million in the establishment of the fund. Huaxia Equity Investment Fund Management (Beijing) Co., Ltd. serves as the general partner, executive partner, and fund manager. Ping An Bank Co., Ltd. is the custodian of the fund.

Joinn Therapeutics notes that the fund’s operation is subject to various factors including macroeconomics, industry cycles, and investment targets, which could lead to investment failure or losses. The company plans to carefully consider advice and fulfill its information disclosure obligations as the project progresses.